Cost of hospitalization for bronchiectasis exacerbation in children
- PMID: 32358912
- DOI: 10.1111/resp.13828
Cost of hospitalization for bronchiectasis exacerbation in children
Abstract
Background and objective: Despite paediatric bronchiectasis being recognized increasingly worldwide, prior reports of hospitalization costs for bronchiectasis in children are lacking. This study aimed to (i) identify health service costs of hospitalizations and (ii) factors associated with these costs in children admitted to an Australian paediatric hospital following an acute exacerbation of their bronchiectasis.
Methods: Demographic and hospital resource use data were prospectively recorded for 100 hospitalizations in 80 children aged <18 years admitted consecutively to the QCH, Brisbane, Australia. Costs (2016 AUD) were obtained from the hospital's Finance Department. Linear regressions, with bootstrap resampling to quantify uncertainty, were used to estimate factors affecting cost of hospitalization.
Results: The 100 hospitalizations (48 males) had a median (IQR) age of 6.04 (4.04-9.85) years. Their mean (SD) LOS was 12.30 (4.60) days. The mean (SD) direct health service cost was AUD 30 182 (13 998) per hospitalization. The greatest contributor to costs was health professional wages, accounting for 70% of the cost per episode. LOS, younger age at admission and number of bronchiectatic lobes affected were associated with higher costs, whilst HITH service was associated with lower cost. The cost to families on average was AUD 2669.50 (SD: 991.50) per hospitalization when accounting for lost wages and opportunity cost.
Conclusion: The per episode healthcare cost burden of hospitalizations for paediatric bronchiectasis exacerbations is substantial. Interventions that prevent hospitalized exacerbations and reduce severity of childhood bronchiectasis with even moderate effectiveness are likely to result in substantial hospital costs savings.
Keywords: bronchiectasis; costs; hospital in the home; hospitalization; paediatric.
© 2020 Asian Pacific Society of Respirology.
Comment in
-
Counting the cost of bronchiectasis.Respirology. 2020 Dec;25(12):1223-1224. doi: 10.1111/resp.13888. Epub 2020 Jun 30. Respirology. 2020. PMID: 32608039 No abstract available.
References
REFERENCES
-
- Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. Pediatric bronchiectasis: no longer an orphan disease. Pediatr. Pulmonol. 2016; 51: 450-69.
-
- McCallum GB, Binks MJ. The epidemiology of chronic suppurative lung disease and bronchiectasis in children and adolescents. Front. Pediatr. 2017; 5: 27.
-
- Martinez-Garcia MA, Polverino E, Aksamit T. Bronchiectasis and chronic airway disease: it is not just about asthma and COPD. Chest 2018; 154: 737-9.
-
- Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O'Mara P, Grimwood K; Extended Voting Group. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines. Med. J. Aust. 2015; 202: 21-3.
-
- Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G et al. Characterization of the "frequent exacerbator phenotype" in bronchiectasis. Am. J. Respir. Crit. Care Med. 2018; 197: 1410-20.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
